Genetic Modification of Tumor-Infiltrating Lymphocytes via Retroviral Transduction.

ABSTRACT: Adoptive T cell therapy (ACT) holds great promise for cancer treatment. One approach, which has regained wide interest in recent years, employs antitumor T cells isolated from tumor lesions ("tumor-infiltrating lymphocytes" or TIL). It is now appreciated that a considerable proportion of anti-melanoma TIL recognize new HLA-binding peptides resulting from somatic mutations, which occurred during tumor progression. The clinical efficacy of TIL can potentially be improved via their genetic modification, designed to enhance their survival, homing capacity, resistance to suppression, tumor killing ability and additional properties of clinical relevance. Successful implementation of such gene-based strategies critically depends on efficient and reproducible protocols for gene delivery int

SUBMITTER: Weinstein-Marom H 

PROVIDER: S-EPMC7817656 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature